- Home
- SKHY vs JNJ Comparison
SKHY vs JNJ Comparison
Compare SKHY & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKHY | JNJ |
|---|---|---|
| Founded | N/A | 1886 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.0B | 542.4B |
| IPO Year | 2026 | 2003 |
Fundamental Metrics
Financial Performance| Metric | SKHY | JNJ |
|---|---|---|
| Price | $162.65 | $260.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $238.20 |
| AVG Volume (30 Days) | ★ 29.2M | 7.6M |
| Earning Date | N/A | 04-14-2026 |
| Dividend Yield | N/A | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 4.41 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.63 |
| Revenue Next Year | N/A | $7.43 |
| P/E Ratio | ★ N/A | $59.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $124.80 | $173.33 |
| 52 Week High | $177.93 | $274.90 |
Technical Indicators
Market Signals| Indicator | SKHY | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 56.38 | 57.19 |
| Support Level | $129.30 | $247.97 |
| Resistance Level | $177.93 | $272.16 |
| Average True Range (ATR) | 10.59 | 5.58 |
| MACD | 1.37 | -0.32 |
| Stochastic Oscillator | 98.94 | 44.36 |
Price Performance
Historical ComparisonAbout SKHY SK hynix Inc. American Depositary Shares
SK Hynix is a semiconductor memory manufacturer with around 60%-70% of its revenue from DRAM and 30%-35% of its revenue from NAND. The company is both the second-largest DRAM and NAND supplier globally, with a 33% and 21% market share, respectively, as of 2024. SK Hynix increased its market position in NAND from fourth to second, after acquiring Intel's NAND business in 2021. SK Square, an investment management company spun off from SK Telecom, is SK Hynix's largest shareholder and currently holds 20% of the company's shares.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.